Staedtisches Klinikum Karlsruhe gGmbH

At Staedtisches Klinikum Karlsruhe gGmbH, a major focus is on hemic and lymphatic diseases, especially acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. The studies are designed to test new treatment strategies, refine risk-adapted care, and improve long-term disease control.

• Advancing treatment options for acute leukemias in both adults and children
• Evaluating new approaches for lymphoma, including relapsed and high-risk disease
• Testing therapies aimed at improving remission depth and survival in multiple myeloma

These trials often compare newer combinations with established care to see whether outcomes can be improved while keeping treatment manageable for patients.

The site also supports extensive research in pediatric neoplasms, with studies in neuroblastoma, medulloblastoma, ependymoma, and childhood renal tumors. This work aims to improve cure rates, reduce relapse risk, and better tailor therapy to disease risk.

• Investigating treatment strategies for high-risk neuroblastoma
• Studying outcome improvement in medulloblastoma and ependymoma
• Refining care for childhood kidney tumors and other rare pediatric cancers

Research in this area focuses on finding more effective and safer treatment paths for children and adolescents with serious cancers.

Clinical trials at this hospital include several solid tumor programs in neoplasms, particularly breast cancer, ovarian cancer, gastric cancer, colorectal cancer, and biliary tract cancer. The research is aimed at improving survival, reducing recurrence, and identifying better ways to personalize treatment.

• Testing new treatment combinations for early and triple-negative breast cancer
• Evaluating therapies for advanced ovarian cancer and biliary tract cancer
• Studying adjuvant approaches in colon cancer and treatment options for gastric cancer

These studies help determine whether newer cancer treatments can improve outcomes compared with standard care.

Another important area is immune system diseases, including trials related to graft-versus-host disease, stem cell transplantation, and long-term follow-up after gene-modified T-cell treatment. This research explores how to improve immune-based therapies and make transplant care safer and more effective.

• Assessing long-term outcomes after cellular immunotherapy
• Improving conditioning and supportive care around allogeneic transplantation
• Studying strategies to reduce complications such as graft-versus-host disease

These trials are especially relevant for patients with difficult-to-treat blood cancers who may benefit from advanced immune-based approaches.

Beyond oncology, the site is also involved in research on cardiovascular diseases and nutritional and metabolic diseases, including chronic kidney disease, hypertension, and related cardiorenal conditions. The goal is to improve disease control, protect organ function, and support better long-term health outcomes.

• Evaluating treatments for chronic kidney disease and albuminuria
• Studying therapies for patients with hypertension and kidney-related risk
• Exploring approaches that may reduce cardiovascular and kidney complications

These trials broaden the research portfolio at Medizinische Klinik III by addressing important non-cancer conditions alongside oncology.